Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Ponz-Sarvise, Mariano, Corbo, Vincenzo, Tiriac, Hervé, Engle, Dannielle D., Frese, Kristopher K., Oni, Tobiloba E., Hwang, Chang-Il, Öhlund, Daniel, Chio, Iok In Christine, Baker, Lindsey A., Filippini, Dea, Wright, Kevin, Bapiro, Tashinga E., Huang, Pearl, Smith, Paul, Yu, Kenneth H., Jodrell, Duncan I, Park, Youngkyu, Tuveson, David A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858952/
https://ncbi.nlm.nih.gov/pubmed/31492749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1398
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge